Site Search

Clinical comparison: SPECTRALIS Ultra-Widefield Angiography Module and Optomap®

The SPECTRALIS® Non-Contact Ultra Widefield Angiography Module was recently introduced to extend the range of clinical applications of the SPECTRALIS and HRA2® multi-modality imaging platforms to meet the increasing need of peripheral imaging to manage patients with retinal vascular, degenerative and inflammatory disease.

In a recent article the group of Szilárd Kiss (Weill Cornell Medical College, New York, USA) compared ultra-widefield fluorescein angiography with this new module to the Optos® Optomap®. Although the findings described in this study are limited to the examination of 10 eyes, the results confirm the excellent performance of the SPECTRALIS non-contact angiography module.

The article can be downloaded here.

The group demonstrated that both ultra-widefield imaging devices “permit excellent capture of the posterior pole as well as the peripheral retinal pathology in a single, non-steered shot.” The small variability in the field-of-view as measured with the SPECTRALIS device is a good indicator that the acquisition of the images is less affected by patient constitution, e.g. lid and lash artifacts.
Qualitatively comparing the field of view of both instruments, the results demonstrate that “the Optos Optomap showed the temporal and nasal retina to a greater extend”, while “the Heidelberg SPECTRALIS was able to image the superior and inferior retina to a more distal point.”

The authors noted peripheral distortion and less detail in the periphery of Optos images. As this distortion may lead to an unnatural representation of retinal structures in the periphery this makes the direct comparison of the captured area in numbers of pixel difficult. In fact, the group pointed out: “In a qualitative evaluation, we found that the Heidelberg ultra-widefield lens outperformed the Optos Optomap in the superior and inferior quadrants, despite a non-statistical quantitative difference [in numbers of pixels measured].”

Dr. Kiss compared the clinical performance of both devices in a patient with multiple retinal hemangioblastomas. Although both instruments enable the clinician a view into the far periphery, for some patients there is the need to look even further to identify the full extent of the disease. The authors demonstrated that this extended view is easily possible with the moveable camera head of the SPECTRALIS. In addition, the clinical value of high-resolution, evenly illuminated and undistorted peripheral images has been effectively demonstrated in order to clearly show all retinal hemangioblastomas during the examination.

Optomap is a registered trademark of Optos Plc.
Witwer MT, Parlitsis G, Patel S, Kiss S. Comparison of ultra-widefield fluorescein angiography with the Heidelberg Spectralis® nocontact ultra-widefield module versus the Optos® Optomap®. Clninical Ophthalmology 2013, 7:389-394.